Short Interest in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Grows By 613.1%

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a large increase in short interest in May. As of May 29th, there was short interest totaling 625,772 shares, an increase of 613.1% from the May 14th total of 87,758 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average trading volume of 38,097,719 shares, the days-to-cover ratio is presently 0.0 days.

Jupiter Neurosciences Trading Down 2.9%

JUNS traded down $0.01 on Wednesday, hitting $0.23. 1,896,991 shares of the company’s stock were exchanged, compared to its average volume of 3,593,414. Jupiter Neurosciences has a fifty-two week low of $0.17 and a fifty-two week high of $3.33. The firm has a 50-day moving average price of $0.33 and a 200-day moving average price of $0.64. The stock has a market cap of $8.16 million, a price-to-earnings ratio of -0.83 and a beta of 1.71.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.23 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Jupiter Neurosciences currently has an average rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Several hedge funds have recently made changes to their positions in the company. Vestor Capital LLC raised its holdings in Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after buying an additional 970,314 shares during the period. Geode Capital Management LLC increased its position in shares of Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after acquiring an additional 28,826 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Jupiter Neurosciences during the fourth quarter valued at about $135,000. Finally, Allen Capital Group LLC acquired a new stake in shares of Jupiter Neurosciences during the fourth quarter valued at about $31,000.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.